×
About 2,645 results

ALLMedicine™ Focal Segmental Glomerulosclerosis Center

Research & Reviews  946 results

T-cell receptor diversity in minimal change disease in the NEPTUNE study.
https://doi.org/10.1007/s00467-022-05696-x
Pediatric Nephrology (Berlin, Germany); Liu S, Bush WS et. al.

Aug 10th, 2022 - Minimal change disease (MCD) is the major cause of childhood idiopathic nephrotic syndrome, which is characterized by massive proteinuria and debilitating edema. Proteinuria in MCD is typically rapidly reversible with corticosteroid therapy, but r...

Focal Segmental Glomerulosclerosis
https://emedicine.medscape.com/article/245915-overview

Aug 9th, 2022 - Practice Essentials Focal segmental glomerulosclerosis (FSGS) is one of the most common causes of primary glomerular disease in adults. [1] In adults undergoing kidney biopsy for evaluation of proteinuria, FSGS accounts for 35% of all cases and up...

Focal Segmental Glomerulosclerosis
http://emedicine.medscape.com/article/245915-overview

Aug 9th, 2022 - Practice Essentials Focal segmental glomerulosclerosis (FSGS) is one of the most common causes of primary glomerular disease in adults. [1] In adults undergoing kidney biopsy for evaluation of proteinuria, FSGS accounts for 35% of all cases and up...

Focal Segmental Glomerulosclerosis Workup
http://emedicine.medscape.com/article/245915-workup

Aug 9th, 2022 - Laboratory Studies In patients with focal segmental glomerulosclerosis (FSGS), urinalysis reveals large amounts of protein, along with hyaline and broad waxy casts, whereas red blood cell (RBC) casts are generally absent. Broad casts may be observ...

Focal Segmental Glomerulosclerosis
https://emedicine.medscape.com/article/245915-print

Aug 9th, 2022 - Practice Essentials Focal segmental glomerulosclerosis (FSGS) is one of the most common causes of primary glomerular disease in adults.[1] In adults undergoing kidney biopsy for evaluation of proteinuria, FSGS accounts for 35% of all cases and up ...

see more →

Guidelines  2 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Impr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983378
Kidney International; Swanepoel CR, Atta MG et. al.

Feb 6th, 2018 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulti...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  70 results

Pathogenesis of Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT00001392

Aug 9th, 2022 - The present protocol seeks to advance our understanding of sclerosing glomerular and tubulointerstitial kidney diseases, including but not limited to variants of focal segmental glomerulosclerosis (FSGS) and chronic kidney disease of unknown etiol...

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Primary Focal Segmental Glomerulosclerosis
https://clinicaltrials.gov/ct2/show/NCT05213624

Aug 9th, 2022 - This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSG...

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
https://clinicaltrials.gov/ct2/show/NCT05003986

Aug 2nd, 2022 - This is a multicenter, open-label, 112-week study of sparsentan in approximately 57 pediatric subjects aged ≥1 year to <18 years with selected proteinuric glomerular diseases, divided into 2 populations, defined as follows: Population 1: Subjects ...

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
https://clinicaltrials.gov/ct2/show/NCT03649152

Jul 29th, 2022 - This study will be evaluating the safety and efficacy of propagermanium for the treatment of participants with FSGS who are already taking irbesartan by: monitoring symptoms that participants may experience while on the study, measuring levels of ...

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
https://clinicaltrials.gov/ct2/show/NCT04009668

Jul 27th, 2022 - The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help develop individualized treatment options for future patient...

see more →

News  33 results

Nephrotic Syndrome Patients at High Risk of Kidney Failure, Vascular Problems
https://www.medscape.com/viewarticle/954056

Jul 1st, 2021 - NEW YORK (Reuters Health) - Adults with primary nephrotic syndrome (NS) had close to a 20 times greater risk of developing kidney failure and higher risks of several cardiovascular diseases and death compared to those without NS in a large analysi...

Protein Predicts Risk of AKI in COVID-19 Patients
https://www.medscape.com/viewarticle/939052

Oct 13th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Admission levels of a specific protein predict the development of acute kidney injury (AKI) as well as the need for dialysis in patients hospitali...

Late-onset neutropenia more common than expected in patients on rituximab
https://www.mdedge.com/rheumatology/article/228758/lupus-connective-tissue-diseases/late-onset-neutropenia-more-common
Steve Cimino

Sep 18th, 2020 - A new study has found that late-onset neutropenia is a notably common and occasionally serious occurrence in rituximab-treated patients with autoimmune diseases. Dr.

24-year-old man • prednisone therapy for nephrotic syndrome • diffuse maculopapular rash • pruritis
https://www.mdedge.com/familymedicine/article/223501/dermatology
MDedge Family Medicine; Neil E. Soifer, MD, Michael J. Hepner, MD

Jun 8th, 2020 - THE CASE A 24-year-old man with no past medical history was referred to a nephrologist for a 5-month history of leg swelling and weight gain. His only medication was furosemide 40 mg/d, prescribed by his primary care physician.

BRIEF-Vifor Pharma: VFMCRP And Chemocentryx Announce Topline Data From Phase-II Lumina-1 Trial Of CCX140 In Focal Segmental Glomerulosclerosis
https://www.reuters.com/article/brief-vifor-pharma-vfmcrp-and-chemocentr/brief-vifor-pharma-vfmcrp-and-chemocentryx-announce-topline-data-from-phase-ii-lumina-1-trial-of-ccx140-in-focal-segmental-glomerulosclerosis-idUSASN0006W6

May 18th, 2020 - May 18 (Reuters) - VIFOR PHARMA AG: * VFMCRP AND CHEMOCENTRYX ANNOUNCE TOPLINE DATA FROM PHASE-II LUMINA-1 TRIAL OF CCX140 IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

see more →

Patient Education  1 results see all →